UNSPSC 51101695: Troquidazole

This classification denotes an antiprotozoal agent with the molecular formula C14H15N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41X4FOR202, chemically known as 4-morpholinecarboximidamide, n-(3-nitro-4-quinolinyl)- but generally known as troquidazole, which bears US NIH Compound Identifier 65903. European Medicines Agency schedules Troquidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11347MIG.

UNSPSC 51101695 Troquidazole, a Commodity code, nominally refers to a specific pharmaceutical active ingredient, but the recent state and local opportunities tagged under this code show little direct alignment with troquidazole procurement itself. Instead, the opportunities reflect pharmaceutical supply chain activity more broadly—warehouse distribution agreements and public health stockpiling of other medications and medical supplies. The issuing bodies are state health departments and county public health authorities soliciting through piggyback cooperative purchasing vehicles and competitive bid processes. The work entails procuring and distributing bulk pharmaceutical products and medical countermeasure systems to support emergency preparedness and community health initiatives, with multi-year contract terms and recurring renewal options typical of government pharmaceutical supply agreements.

Recent activity spans Florida and Illinois. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for Doxycycline Hyclate and Ciprofloxacin Hydrochloride supply under an Invitation for Bid process. Seminole County, Florida issued an IFB (number IFB60459723LAS) posted June 30, 2026, for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly delivery to the Seminole County Community Health Building, with a response deadline of July 26, 2023, at 2:00 pm. The code shows limited recent opportunities; the disconnect between the nominal commodity scope and the actual solicitation mix suggests this code may be misapplied to pharmaceutical distribution and countermeasure procurement that would more accurately map to other pharmaceutical and medical-device categories.